© 2005 Oxford University Press
ARTICLE |
Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti–Epidermal Growth Factor Receptor Antibodies
Affiliations of authors: Department of Pathophysiology (ABR, HK, OS, EJ-J), Department of Surgery (MK), and Clinical Division of Oncology, Department of Medicine I (CCZ), Medical University of Vienna, Vienna, Austria
Correspondence to: Erika Jensen-Jarolim, MD, Department of Pathophysiology, Center of Physiology and Pathophysiology, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria (e-mail: erika.jensen-jarolim{at}meduniwien.ac.at).
Background: The monoclonal antibody cetuximab (IMC-225, Erbitux) inhibits epidermal growth factor receptor (EGFR) signaling and has been approved for metastatic colon cancer therapy. However, to achieve effective titers, passive antibody therapies must be repeatedly administered over long periods. To overcome this limitation, we aimed to generate a vaccine inducing continuously available "cetuximab-like" antibodies in vivo using the mimotope approach. Methods: We used the phage display technique to identify four peptides structurally mimicking the cetuximab epitope. We coupled two of these peptides to an immunogenic carrier protein, and we vaccinated four groups (n = 8) of BALB/c mice intraperitoneally with 10 µg of the mimotope conjugates, a control peptide conjugate, or the carrier protein alone. We assessed antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity mediated by the induced antibodies against EGFR-overexpressing human A431 carcinoma cells. We then tested receptor internalization capacity of the induced antibodies with fluorescently labeled EGFR, and we assayed their growth inhibitory potential toward A431 cells with a [3H]thymidine proliferation assay. Results: Mimotope-induced antibodies recognized EGFR, and both types of antibody-mediated cytotoxic effects were elicited by these antibodies. In both cellular cytotoxicity assays, the mimotope-induced antibodies exhibited specific lysis of more than 50%. The induced antibodies caused internalization of the receptor from the cell surface into endocytic vesicles and inhibited growth of EGFR-expressing cells to a similar extent as cetuximab [67% (95% confidence interval {CI} = 55% to 79%) and 69% (95% CI = 55% to 84%), respectively]. Conclusions: Epitope-specific immunization is feasible for active anti-EGFR immunotherapy. The in vitro biologic features of mimotope-induced antibodies are similar to those of the monoclonal antibody cetuximab.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Wagner, C. Krepler, D. Allwardt, J. Latzka, S. Strommer, O. Scheiner, H. Pehamberger, U. Wiedermann, C. Hafner, and H. Breiteneder Reduction of Human Melanoma Tumor Growth in Severe Combined Immunodeficient Mice by Passive Transfer of Antibodies Induced by a High Molecular Weight Melanoma-Associated Antigen Mimotope Vaccine Clin. Cancer Res., December 15, 2008; 14(24): 8178 - 8183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Correale, P. Tagliaferri, A. Fioravanti, M. T. Del Vecchio, C. Remondo, F. Montagnani, M. S. Rotundo, C. Ginanneschi, I. Martellucci, E. Francini, et al. Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) Clin. Cancer Res., July 1, 2008; 14(13): 4192 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Bramswig, R. Knittelfelder, S. Gruber, E. Untersmayr, A. B. Riemer, K. Szalai, R. Horvat, R. Kammerer, W. Zimmermann, C. C. Zielinski, et al. Immunization with Mimotopes Prevents Growth of Carcinoembryonic Antigen Positive Tumors in BALB/c Mice Clin. Cancer Res., November 1, 2007; 13(21): 6501 - 6508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Binder, F.-N. Vogtle, S. Michelfelder, F. Muller, G. Illerhaus, S. Sundararajan, R. Mertelsmann, and M. Trepel Identification of Their Epitope Reveals the Structural Basis for the Mechanism of Action of the Immunosuppressive Antibodies Basiliximab and Daclizumab Cancer Res., April 15, 2007; 67(8): 3518 - 3523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Riemer, E. Untersmayr, R. Knittelfelder, A. Duschl, H. Pehamberger, C. C. Zielinski, O. Scheiner, and E. Jensen-Jarolim Active Induction of Tumor-Specific IgE Antibodies by Oral Mimotope Vaccination Cancer Res., April 1, 2007; 67(7): 3406 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Luo, E. Ko, J. C.-f. Hsu, X. Wang, and S. Ferrone Targeting Melanoma Cells with Human High Molecular Weight-Melanoma Associated Antigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects J. Immunol., May 15, 2006; 176(10): 6046 - 6054. [Abstract] [Full Text] [PDF]
|
|